Frishman W H, Rapier R C
Albert Einstein College of Medicine, Bronx, New York.
Med Clin North Am. 1989 Mar;73(2):437-48. doi: 10.1016/s0025-7125(16)30681-2.
Increased levels of cholesterol, LDL-cholesterol, and VLDL-cholesterol are known risk factors for the development of coronary artery disease. There are multiple drugs that can be used for lowering cholesterol, including lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme step in cholesterol synthesis in the body. The pharmacology of this novel agent is discussed in this article.
胆固醇、低密度脂蛋白胆固醇和极低密度脂蛋白胆固醇水平升高是已知的冠状动脉疾病发病风险因素。有多种药物可用于降低胆固醇，包括洛伐他汀，它是3-羟基-3-甲基戊二酰辅酶A还原酶的竞争性抑制剂，该酶是体内胆固醇合成中的限速酶步骤。本文讨论了这种新型药物的药理学。
